Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.

No abstract is available for this paper.

• Publication year

  1975

• Venue

  Advances in neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 1096574
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Neurochemical Mechanisms of Tremor in Parkinson’s Disease

  2025cites this paper
• [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].

  2017cites this paper
• Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease

  2016cites this paper
• Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study

  2006cites this paper
• Differential regional and kinetics effects of piribedil and bromocriptine on dopamine metabolites: a brain microdialysis study in freely moving rats

  2005cites this paper
• Activité et acceptabilité du piribédil dans la maladie de Parkinson: étude multicentrique

  2004cites this paper
• Maladie de Parkinson: mécanismes physiopathologiques et effets du piribédil

  2004cites this paper
• Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian type

  2003cites this paper
• Quantitative rest activity in ambulatory monitoring as a physiological marker of restless legs syndrome: A controlled study

  2003cites this paper
• Factors associated with increased risk of head tremor in essential tremor: A community‐based study in northern Manhattan

  2003cites this paper
• Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled study

  2003cites this paper
• Higher incidence of depression preceding the onset of Parkinson's disease: A register study

  2003cites this paper
• Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation

  2002cites this paper
• Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease

  2001cites this paper
• Transdermal Administration of Piribedil Reverses MPTP-induced Motor Deficits in the Common Marmoset

  2000cites this paper
• An appraisal of the antiparkinsonian activity of piribedil in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets

  1996cites this paper
• Different effects of dopamine and piribedil (a dopamine D2 agonist) on frog monocular optokinetic nystagmus asymmetry.

  1995cites this paper
• Activity and acceptability of piribedil in Parkinson's disease: a multicentre study

  1992cites this paper
• Parkinson's disease: pathological mechanisms and actions of piribedil

  1992cites this paper
• Piribedil: behavioural, neurochemical and clinical profile of a dopamine agonist.

  1983cites this paper
• Cerebrospinal Fluid Studies in Parkinson’s DiseaseNorepinephrine and γ-Aminobutyric Acid Concentrations

  1980cites this paper
• Die Wirkung von Piribedil auf den Parkinson-Tremor

  1980cites this paper
• A comparative clinical investigation of the therapeutic effect of levodopa alone and in combination with a decarboxylase inhibitor (carbidopa) in cases of Parkinson's disease.

  1978cites this paper
• Effects of a dopamine agonist piribedil in depressed patients: relationship of pretreatment homovanillic acid to antidepressant response.

  1978cites this paper
• Piribedil

  1976cites this paper
• DA agonists ‐ Non‐Ergot derivaties: Piribedil

  year unknowncites this paper